Avelumab and Merkel Cell Carcinoma: Examining the Evidence for Causation
From General Health Literacy to Occupational Exposure Concerns
The legacy of general health and science information has long provided a foundation for public understanding of wellness and disease prevention. Within this broad context, discussions of therapeutic agents and their potential unintended effects have typically been framed in terms of patient safety and pharmacovigilance. As scientific inquiry advances, the focus naturally extends from clinical populations to broader environmental and occupational settings where chemical exposures may occur. In the domain of mass production, workers may encounter substances that, while beneficial in controlled medical contexts, warrant careful evaluation when present in industrial environments. This transition from general health literacy to specific exposure concerns is particularly relevant when considering immunomodulatory compounds. The shift in perspective moves from understanding a drug’s therapeutic profile in patients to assessing its implications for those who handle or are otherwise exposed during manufacturing processes. Such a pivot requires a neutral examination of available data, without presupposing causal mechanisms, to inform risk assessment practices.
Bridging to Avelumab: A Therapeutic Agent Under Scrutiny
The following discussion narrows this lens to consider occupational exposure to avelumab and the associated questions regarding Merkel cell carcinoma risk, as illuminated by current research findings. Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for use in this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).
Merkel Cell Carcinoma: Etiology and Epidemiology
Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus; approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study of five patients treated at three different academic sites in Germany, three out of five patients who were refractory to avelumab and later treated with combined ipilimumab and nivolumab responded according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported on ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/).
Mechanistic Pathways and Risk Context
The mechanistic pathways linking avelumab to Merkel cell carcinoma are centered on its role as an immune checkpoint inhibitor. Avelumab blocks PD-L1, thereby enhancing T-cell responses against tumor cells. In MCC, T-cell responses are critical for tumor control, and immune checkpoint inhibitors improve overall response rates and duration of responses compared with conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385/). Nevertheless, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). The development of immune-related adverse events is a known risk of avelumab therapy, and these events can affect various organ systems. The adequacy of warnings regarding avelumab and Merkel cell carcinoma is reflected in the drug's prescribing information, which includes warnings about immune-mediated adverse reactions. However, the specific risk of developing Merkel cell carcinoma as a consequence of avelumab treatment is not supported by the available evidence; rather, avelumab is used to treat existing MCC. The evidence indicates that avelumab is a therapeutic agent for MCC, not a cause of the disease. Causation-related considerations for affected patients therefore focus on the drug's efficacy and safety in treating MCC, not on a causal link between avelumab and the development of MCC. The timeline between exposure to avelumab and documented harm is relevant to the occurrence of immune-related adverse events, which can occur at any time during treatment. In the JAVELIN Merkel 200 trial, responses were observed in approximately one-third of patients, indicating that the drug can be effective within a treatment cycle. For patients who do not respond or who progress on avelumab, the timeline to progression varies. In the retrospective study of avelumab-refractory patients, subsequent treatment with ipilimumab and nivolumab was administered after documented progression on avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). The evidence does not provide a specific timeline for the development of immune-related adverse events, but these are known to occur during the course of treatment.
Summary of Evidence and Implications
In summary, avelumab is an approved and effective treatment for metastatic Merkel cell carcinoma, with a mechanism of action involving PD-L1 blockade. The evidence does not support a causal relationship between avelumab and the development of Merkel cell carcinoma; rather, the drug is used to treat the disease. Risks associated with avelumab include immune-related adverse events and lack of response in approximately 50% of patients. For patients who are refractory to avelumab, alternative treatments such as combined ipilimumab and nivolumab may offer benefit.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Can avelumab cause Merkel cell carcinoma?
No, the available evidence does not support a causal relationship between avelumab and the development of Merkel cell carcinoma. Avelumab is used to treat existing MCC, not cause it. (https://pubmed.ncbi.nlm.nih.gov/29799096/)
What is the mechanism of action of avelumab in Merkel cell carcinoma?
Avelumab blocks PD-L1, enhancing T-cell responses against tumor cells. This immune checkpoint inhibition improves response rates and duration of responses in MCC patients. (https://pubmed.ncbi.nlm.nih.gov/34445385/)
What are the risks of avelumab treatment?
Risks include immune-related adverse events affecting various organ systems and lack of response in approximately 50% of patients. (https://pubmed.ncbi.nlm.nih.gov/35877101/)
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Free and confidential. No obligation — an initial records screening only.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.